The British newspaper, “Daily Mail”, revealed that AstraZenecaAstraZeneca Asked the US Food and Drug AdministrationFDA The first ever preventive drug for the Corona virus was licensed, after trials showed that treatment with monoclonal antibodies reduced the risk of symptoms by 77%.
New drug AstraZeneca
The newspaper said, “I have requested AstraZeneca.” AstraZenecaFrom the American authority (FDA) Approval of a new treatment, which reduces the risk of developing symptoms of corona by 77%.
And this treatment, which uses antibodies made in the laboratory to protect against symptoms of corona, is likely to be limited to people with weakened immune systems, adding: The demand for other monoclonal antibody treatments has increased in the United States in recent months. For the treatment of unvaccinated patients.
The newspaper said, the new treatment is not intended to be used in place of vaccines, but it works alongside the vaccine for those most vulnerable to infection with the Corona virus.
The newspaper pointed out that this drug uses proteins of the laboratory immune system to protect patients from developing symptoms of corona, for people with weak immune systems, as laboratory experiments showed that the drug reduced the risk of symptoms by 77%, and monoclonal antibody treatments have become used on widespread in the United States during the last delta wave.
These treatments include antibodies made in the laboratory and immune system proteins designed to fight off infection with the Corona virus, and when injected into a patient, the antibodies can boost the patient’s immune system, reducing the risk of severe symptoms of Corona.
She noted that during the recent Corona wave, states such as Florida and Texas made monoclonal antibodies an important part of epidemic prevention strategies, and 7 states, including Florida, Texas and 5 other southern states – accounted for 70% of requests for monoclonal antibody treatment in early September.
The newspaper said, the Department of Health and Human Services (DHS)HHS) by restricting access to treatments as a result.
And the newspaper said, the new treatment from the British company AstraZeneca may help meet this demand and prevent corona infection in some of the most vulnerable Americans..
And she confirmed, that the treatment, called AZD7442 It differs from other monoclonal antibody drugs in that it acts proactively over a long period of time, providing protection from coronavirus for up to a year..
AstraZeneca announced Tuesday that it has applied for an emergency use authorization to the U.S. Food and Drug Administration, adding that if approved by the U.S. Food and Drug Administration, the treatment would likely be limited to people with weakened immune systems who do not receive adequate protection from vaccination..
And the newspaper said, that unlike the monoclonal antibodies currently authorized in the United States and which are used by Corona patients after they contract the virus, AstraZeneca will be AstraZeneca As a preventative treatment for the most vulnerable Americans, a recent clinical trial shows AstraZeneca’s two antibody combinations AstraZeneca Reduced the risk of patients contracting symptomatic coronavirus by 77%.